Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiplicom Launches Two New Diagnostic Kits

Published: Tuesday, June 03, 2014
Last Updated: Tuesday, June 03, 2014
Bookmark and Share
Company aims for strong growth in the rapidly expanding molecular diagnostic market.

Multiplicom NV has announced that it has achieved ISO 13485 accreditation, and is launching two new CE/IVD labeled DNA mutation detection kits for Cystic Fibrosis (CF) and Familial Mediterranean Fever (FMF), genetics diseases with a high carrier rate.

Dr Dirk Pollet, CEO of Multiplicom, said: “Having ISO 13485 accreditation establishes Multiplicom as a reliable supplier of diagnostic kits to clinical labs as well as to the major diagnostic companies worldwide. All Multiplicom MASTR products have a uniform protocol, require only standard equipment and are compatible with MPS equipment from Roche, Illumina and Thermo Fisher. The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in the routine clinical labs, enabling personalized medicine.”

Multiplicom was recently awarded ISO 13485:2003 and ISO 13485:2012 certification for “Design, development, manufacturing and distribution of in vitro molecular diagnostic test kits used for the identification of genomic and somatic variants.”

This week, at the European Society for Human Genetics in Milan, Multiplicom has announced the launch of two new CE/IVD labeled MASTR kits, for the comprehensive detection of mutations associated with CF in June and FMF in July. With these new CE/IVD labeled kits Multiplicom aims to take a significant market share in the screening markets for both diseases.

Multiplicom is operating in an area of rapid growth. The European MPS diagnostic market is expected to grow from €20M in 2012 to >€2,000M in 2018 (CAGR% >100%) within a worldwide market of >€6,000M in 2018.

Based on its success in Europe, with expected sales in 2014 of > €6M (CAGR%>100%), the ISO 13485 accreditation and the launch of new products for both genomic and somatic mutations, Multiplicom is now in pole position for additional growth in other major territories.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom Appoints Board Chairman
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.
Thursday, June 27, 2013
Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!